Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-23

Clinical Trial Update: Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome [NA]

View source ↗

Summary

A clinical trial update for Naglazyme after allo-transplant in Maroteaux-Lamy Syndrome has been terminated, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NAGLAZYME (GALSULFASE)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Maroteaux-Lamy Syndrome | NA | Status: TERMINATED | Results posted: 2020-12-23